AUTHOR=Quindós Guillermo , Miranda-Cadena Katherine , San-Millán Rosario , Borroto-Esoda Katyna , Cantón Emilia , Linares-Sicilia María José , Hamprecht Axel , Montesinos Isabel , Tortorano Anna Maria , Prigitano Anna , Vidal-García Matxalen , Marcos-Arias Cristina , Guridi Andrea , Sanchez-Reus Ferran , Machuca-Bárcena Jesús , Rodríguez-Iglesias Manuel Antonio , Martín-Mazuelos Estrella , Castro-Méndez Carmen , López-Soria Leyre , Ruiz-Gaitán Alba , Fernandez-Rivero Marcelo , Lorenzo Damaris , Capilla Javier , Rezusta Antonio , Pemán Javier , Guarro Josep , Pereira Joana , Pais Célia , Romeo Orazio , Ezpeleta Guillermo , Jauregizar Nerea , Angulo David , Eraso Elena 

TITLE=In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study

JOURNAL=Frontiers in Cellular and Infection Microbiology

VOLUME=Volume 12 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2022.906563

DOI=10.3389/fcimb.2022.906563

ISSN=2235-2988

ABSTRACT=Background: Ibrexafungerp (SCY-078) is the newest oral and intravenous antifungal drug with broad activity, currently undergoing clinical trials for invasive candidiasis.
Objectives: To assess the in vitro activity of ibrexafungerp and comparators against a collection of 434 European blood isolates of Candida.
Methods: Ibrexafungerp, caspofungin, fluconazole and micafungin MICs were collected from 12 European laboratories for 434 blood isolates, including 163 Candida albicans, 108 Candida parapsilosis, 60 Candida glabrata, 40 Candida tropicalis, 29 Candida krusei, 20 Candida orthopsilosis, 6 Candida guilliermondii, 2 Candida famata, 2 Candida lusitaniae, and 1 isolate each of Candida bracarensis, Candida catenulata, Candida dubliniensis, and Candida kefyr. MICs were determined by EUCAST broth microdilution method, and isolates classified according to recommended clinical break-points and epidemiological cut-offs. Additionally, 22 Candida auris from different clinical specimens were evaluated.
Results: Ibrexafungerp MICs ranged from 0.016 to ≥8 mg/L. The lowest ibrexafungerp MICs were observed for C. albicans (geometric MIC 0.062 mg/L, MIC range 0.016-0.5 mg/L) and the highest for C. tropicalis (geometric MIC 0.517 mg/L, MIC range 0.06-≥8 mg/L). Modal MICs/MIC50s (mg/L) against Candida spp. were 0.125/0.06 for C. albicans, 0.5/0.5 for C. parapsilosis, 0.25/0.25 for C. glabrata, 0.5/0.5 for C. tropicalis, 1/1 for C. krusei, 4/2 for C. orthopsilosis, and 0.5/0.5 for C. auris. Ibrexafungerp showed activity against fluconazole- and echinocandin-resistant isolates. If adopting wild type upper limits, a non-wild type phenotype for ibrexafungerp was only observed for 16/434 (3.7%) isolates: 11 (4.6%) C. parapsilosis, 4 (5%) C. glabrata, and 1 (2.5%) C. tropicalis.
Conclusion: Ibrexafungerp showed a potent in vitro activity against Candida.